MHRA Notifies Chiron of Continuing Suspension of Liverpool License for Influenza Vaccines; Suspension May Be Lifted If Compliance with License Demonstrated

Article

EMERYVILLE, Calif. --

Chiron Corporation announced that it has received notice from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) that the MHRA proposes to continue the suspension of the company's license to manufacture influenza vaccines in Liverpool for a further period of three months, effective January 4, 2005, at the same time as the expiration of the initial three-month suspension.

A spokesperson for the UK Department of Health stated that the extension of the suspension "does not result from any newly identified safety issues or findings at the Liverpool plant," and called it "routine regulatory action" that will give Chiron more time to carry out its remediation plan, which is currently underway. The spokesperson also stated that the suspension could be lifted at any time upon satisfactory compliance with the facility's license. The MHRA has worked closely with the U.S. Food and Drug Administration (FDA) on these issues, and the agencies plan to examine progress at the facility throughout the remediation process.

In order to meet timelines for delivery of FLUVIRIN® influenza virus vaccine for the U.S. market, production must begin no later than early spring of 2005. The MHRA notice fulfills an agency requirement to allow Chiron a 28-day period to appeal the notice. Chiron does not intend to pursue this option.

Source: Chiron

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.